Senior Citizen's Guide to Pittsburgh Fall/Winter Edition 2015-16 - page 47

Boomers Resource Guide
• Fall/Winter 2015-16
45
Di abe t i c Macu l a r Edema
(DME) is one of the leading causes
of vision loss in the working age
population. A chronic disease,
diabetes can cause bleeding and
swelling in the back part of the
eye, which is known as the retina.
The accumulation of fluid can lead
to devastating vision loss and ulti-
mately blindness if left untreated.
Over the past few years, clini-
cal trials that have resulted in the
September 2014 approval by the
Food and Drug Administration of
ILUVIEN 0.19mg (fluocinolone
acetonide intravitreal injection,
Alimera Sciences, Alpharetta, GA)
for the treatment of Diabetic Macu-
lar Edema. The drug previously
approved in Europe releases a small
and sustained dose of medication
over a period of 36 months.
Current treatments for DME
include monthly intravitreal injec-
tions that deposit a small dose of
medicine behind the lens of the eye.
Due to the limited amount of medi-
cine injected at each treatment,
the effect is limited and repeated
injections are required to sustain
the desired effect. Laser therapy has
also shown to have limited efficacy
and a longer duration for visual
recovery when compared to newer
injectable medications. This medi-
cation may supplement or replace
previously existing treatments of
monthly intravitreal injections or
laser therapy.
The clinical trials demonstrated
that ILUVIEN can improve visual
acuity by over 2 lines on the eye
chart in 25% of patients as early
as one month. As many as 60%
of patients improved by 2 lines or
more on the eye chart by 9 months
after only a single injection of
ILUVIEN. The sustained release in-
travitreal steroid implant decreases
the chemical signals the diseased
eye produces. Such effects lead to
decreased blood vessels leakage
and retinal swelling.
The injection of ILUVIEN is a
simple, short and painless in office
procedure that is no different in
preparation that the standard in-
travitreal injection for diabetic eye
disease. The medication consists of
a cylindrical implant smaller than a
Vision Saving Treatment for Diabetes
• • • • • • • • • • • • • • • • •
As many as 60% of
patients improved by
2 lines or more on the
eye chart by 9 months
after only a single
injection of ILUVIEN.
• • • • • • • • • • • • • • • • •
1...,37,38,39,40,41,42,43,44,45,46 48,49,50,51,52,53,54,55,56,57,...64
Powered by FlippingBook